Global NAD+ Enhancer Market Growth 2025-2031

The global NAD+ Enhancer market size is predicted to grow from US$ 564 million in 2025 to US$ 1355 million in 2031; it is expected to grow at a CAGR of 15.7% from 2025 to 2031.

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells. It plays a crucial role in various biological processes, including energy metabolism, DNA repair, and gene expression. Some people are interested in NAD+ enhancers, which are substances or compounds that may support or increase the levels of NAD+ in the body.

For the NAD+ Enhancer industry, the market is highly concentrated. The leading companies globally include:

• GeneHarbor
• Chromadex
• Mirailab Bioscience Inc. (Shinkowa Pharmaceutical)

The Top 5 players accounted for about 41% of the market. There are several types of NAD+ Enhancer. The market can be segmented into:

1. Content <98%
2. Content ≥98%

Content ≥98% are the most commonly used type, accounting for 93% of the market share in 2022.

By application, Health Care Products are the largest downstream application area, with a consumption market share of 84% in 2022.

Segmentation by Region:

• Americas:
• United States
• Canada
• Mexico
• Brazil
• APAC:
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe:
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa:
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Key Questions Addressed in this Report:

• What is the 10-year outlook for the global NAD+ Enhancer market?
• What factors are driving NAD+ Enhancer market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do NAD+ Enhancer market opportunities vary by end market size?
• How does NAD+ Enhancer break out by Type, by Application?